135A Stock Overview
A biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
SCYNEXIS, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.16 |
| 52 Week High | US$2.50 |
| 52 Week Low | US$1.09 |
| Beta | 1.5 |
| 11 Month Change | -11.64% |
| 3 Month Change | -10.97% |
| 1 Year Change | -21.45% |
| 33 Year Change | -82.03% |
| 5 Year Change | -87.78% |
| Change since IPO | -98.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| 135A | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 7.0% | -0.3% | 0.8% |
| 1Y | -21.4% | -18.3% | 8.6% |
Return vs Industry: 135A underperformed the German Pharmaceuticals industry which returned -18.4% over the past year.
Return vs Market: 135A underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| 135A volatility | |
|---|---|
| 135A Average Weekly Movement | 8.0% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 135A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 135A's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 29 | David Angulo | www.scynexis.com |
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company’s lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.
SCYNEXIS, Inc. Fundamentals Summary
| 135A fundamental statistics | |
|---|---|
| Market cap | €44.92m |
| Earnings (TTM) | -€34.78m |
| Revenue (TTM) | €8.18m |
5.6x
P/S Ratio-1.3x
P/E RatioIs 135A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 135A income statement (TTM) | |
|---|---|
| Revenue | US$8.57m |
| Cost of Revenue | US$14.68m |
| Gross Profit | -US$6.12m |
| Other Expenses | US$30.32m |
| Earnings | -US$36.44m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.96 |
| Gross Margin | -71.42% |
| Net Profit Margin | -425.41% |
| Debt/Equity Ratio | 22.6% |
How did 135A perform over the long term?
See historical performance and comparison